Rx00150 - Melphalan


Name:
Melphalan
Rx ID:
Rx00150
Validation Level:
Phenomic Similarity:
0.503
Reference ID:
DB01042
Primary Indications:
Multiple myeloma; non-resectable epithelial carcinoma of the ovary; Breast cancer; recurrent in-transit metastatic melanoma of the extremities; unresectable in-transit metastatic melanoma of the extremities; amyloidosis
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Metastatic melanoma of the extremity; hematopoietic stem cell transplantation; cutaneous melanoma; ocular melanoma; uveal melanoma; neuroendocrine tumors
Common Indications:
Multiple myeloma; non-resectable epithelial carcinoma of the ovary
Drug Interactions:
Bendamustine; Cyclosporine Trastuzumab;
Food Interactions:
Take on an empty stomach. Food decreases bioavailabilty by approximately 30%. Increase liquid intake.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00150
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
recurrent in-transit metastatic melanoma of the extremities metastatic melanoma of the extremity 1865 1865 1865 2163.498 0 0.0
breast cancer non-resectable epithelial carcinoma of the ovary 574 22462 5625 18.331 0 0.0
amyloidosis multiple myeloma 207 859 3327 292.254 0 0.0
unresectable in-transit metastatic melanoma of the extremities metastatic melanoma of the extremity 1865 1865 1865 2163.498 0 0.0
multiple myeloma cutaneous melanoma 40 3327 2544 19.069 1.95E-36 6.27e-33
non-resectable epithelial carcinoma of the ovary cutaneous melanoma 20 5625 2544 5.639 1.53E-09 4.92e-06

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
MULTIPLE MYELOMA NEUROENDOCRINE TUMORS 8.43e-41 ABCB1, AHR, BAX, BRAF, CASP10, CASP3, CASP8, CASP9, CCND1, CCR7, CD28, CDKN1A, CDKN2A, CDKN2C, COL18A1, CTLA4, CXCL12, CXCR4, CYP17A1, CYP1A1, CYP1B1, CYP2D6, CYP3A4, CYP3A5, EPHX1, ERCC1, ERCC2, ERCC5, F5, FAS, FASLG, GSTM1, GSTP1, GSTT1, HLA-C, HLA-DQB1, HLA-DRB1, ICAM1, IFNG, IGF1, IGFBP3, IL10, IL12A, IL12B, IL1B, IL1RN, IL2, IL4, IL4R, IL6, IL6R, IL8, IRF4, ITGA6, JAK3, KRAS, LIG4, LTA, MMP2, MPO, MTHFR, MTR, MTRR, NAT1, NAT2, NFKB1, NFKBIA, NOTCH1, NQO1, NRAS, PDGFRA, PPARG, PPP1R13L, PTGS2, RB1, SERPINB2, SERPINE1, SMARCB1, TERT, TGFB1, TLR2, TLR4, TNF, TNFRSF1B, TP53, TYMS, VDR, VEGFA, XPA, XRCC1, XRCC3, XRCC4
BREAST CANCER NEUROENDOCRINE TUMORS 5.89e-08 AKT1, ATM, BARD1, BRCA2, BRIP1, CASP8, CDKN2B-AS1, CHEK2, ERBB4, ESR1, FGFR2, FTO, KRAS, MDM4, PALB2, PHB, PIK3CA, RAD51, TERT, TET2, TP53, XRCC3
AMYLOIDOSIS MULTIPLE MYELOMA 4.58e-06 B4GALT1, CYP2C19, HLA-DRB1, IGKV@, IGLV@, IL1A, IL1B, IL1RN, IL6, MBL2, MEFV, PON1, SERPINE1, TGFB1, TLR2, TLR4, TNF, TNFRSF1A, VEGFA

Chemical, Pharmacological and Biological Annotations


ATC Code:
L01AA03
Categories:
No categories annotated in DrugBank
ChEBI ID:
28876
KEGG Drug ID:
D00369
SMILE:
N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
InChI:
1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Phenylpropanoids and Polyketides
Class:
Phenylpropanoic Acids
Subclass:
Indication:
For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment ...
Click to show more...
Pharmacodynamics:
Melphalan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions prese...
Click to show more...
Description:
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential car...
Click to show more...
Mechanism:
Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases (primarily at the N-7 position of guanine and to a lesser extent, at the N-3 position of adenine), forming monoadducts and resulting in the DNA...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
-
Caco-2 permeable:
+
P-glycoprotein substrate:
Substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
3.9179 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor